An evaluation of methods for determining reference intervals for light transmission platelet aggregation tests on samples with normal or reduced platelet counts

Summary

Light transmission platelet aggregation tests are important for diagnosing platelet function defects. However, uncertainties exist about the best procedures to determine aggregation reference intervals. We investigated methods for determining reference intervals for light transmission aggregation tests, using the % maximal aggregation values for prospectively collected data on healthy control samples. Reference intervals for samples tested at 250 x 10⁹ platelets/l were determined by mean ± 2 standard deviations and non-parametric analyses. To establish reference intervals for tests on thrombocytopenic subjects, regression analyses were used to estimate 95% confidence limits for % maximal aggregation, according to sample platelet counts, using data for control samples diluted to match the platelet count of undiluted thrombocytopenic patient platelet-rich plasma samples. For samples tested at 250 x 10⁹ platelets/l, non-parametric analyses described 95% of data for healthy control samples better than mean ± 2 standard deviations. For samples tested at lower counts, to match thrombocytopenic samples, the % maximal aggregation was influenced by platelet count and derived limits were wider at very low platelet counts for almost all agonists. With ristocetin, it proved feasible to test samples with very low platelet counts to exclude Bernard-Soulier syndrome and type 2B von Willebrand disease. Non-parametric analyses should be the preferred method to establish light transmission aggregation reference intervals for samples tested at normal platelet counts. The derived limits for thrombocytopenic samples provide guidance for evaluating thrombocytopenic platelet function disorders, including which agonists to test, based on the sample platelet count.

Keywords

Platelet function - platelet aggregation - maximal aggregation - reference intervals - thrombocytopenia

• References

• 1 Hayward CP, Rao AK, Cattaneo M. Congenital platelet disorders: overview of their mechanisms, diagnostic evaluation and treatment. Haemophilia 2006; 12 (Suppl. 03) 128-136.
• 2 Moffat KA, Ledford-Kraemer MR, Nichols WL. et al. Variability in clinical laboratory practice in testing for disorders of platelet function: results of two surveys of the North American Specialized Coagulation Laboratory Association. Thromb Haemost 2005; 93: 549-553.
• 3 Hayward CP, Eikelboom J. Platelet function testing: quality assurance. Semin Thromb Hemost 2007; 33: 273-282.
• 4 Nurden P, Nurden AT. Congenital disorders associated with platelet dysfunctions. Thromb Haemost 2008; 99: 253-263.
• 5 bGuidelines on platelet function testing. The British Society for Hematology, BCSH Haemostasis and Thrombosis Task Force. J Clin Path 1998; 41: 1322-1330.
• 6 Jennings LK, McCabe White M. Platelet aggregation. Platelets. 2 ed. Amsterdam: Elsevier; 2007: 495-507.
• 7 Taylor JM, Cumberland WG, Meng X. et al. Normal range estimation for repeated immunologic measures. Clin Diagn Lab Immunol 1996; 03: 139-142.
• 8 Gupta PK, Charan VD, Saxena R. Spectrum of von Willebrand disease and inherited platelet function disorders amongst Indian bleeders. Ann Hematol 2007; 86: 403-407.
• 9 Philipp CS, Dilley A, Miller CH. et al. Platelet functional defects in women with unexplained menorrhagia. J Thromb Haemost 2003; 01: 477-484.
• 10 Mikhail S, Varadarajan R, Kouides P. The prevalence of disorders of haemostasis in adolescents with menorrhagia referred to a haemophilia treatment centre. Haemophilia 2007; 13: 627-632.
• 11 Quiroga T, Goycoolea M, Panes O. et al. High prevalence of bleeders of unknown cause among patients with inherited mucocutaneous bleeding. A prospective study of 280 patients and 299 controls. Haematologica 2007; 92: 357-365.
• 12 Bray PF, Mathias RA, Faraday N. et al. Heritability of platelet function in families with premature coronary artery disease. J Thromb Haemost 2007; 05: 1617-1623.
• 13 Yee DL, Sun CW, Bergeron AL. et al. Aggregometry detects platelet hyperreactivity in healthy individuals. Blood 2005; 106: 2723-2729.
• 14 Gurbel PA, Becker RC, Mann KG. et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007; 50: 1822-1834.
• 15 Cattaneo M, Lecchi A, Zighetti ML. et al. Platelet aggregation studies: autologous platelet-poor plasma inhibits platelet aggregation when added to plateletrich plasma to normalize platelet count. Haematologica 2007; 92: 694-697.
• 16 Linnemann B, Schwonberg J, Mani H. et al. Standardization of light transmittance aggregometry for monitoring antiplatelet therapy: an adjustment for platelet count is not necessary. J Thromb Haemost 2008; 06: 677-683.
• 17 Favaloro EJ, Bonar R, Meiring M. et al. 2B or not 2B? Disparate discrimination of functional VWF discordance using different assay panels or methodologies may lead to success or failure in the early identification of type 2B VWD. Thromb Haemost 2007; 98: 346-358.
• 18 Diamandis M, Veljkovic DK, Maurer-Spurej E. et al. The Quebec Platelet Disorder: Features, pathogenesis and treatment. Blood Coagulation Fibrinolysis 2008; 19: 109-119.
• 19 Horn PS, Pesce AJ. Reference intervals: an update. Clin Chim Acta 2003; 334: 5-23.